Altamira Therapeutics has priced a public offering of approximately $5 million in shares. The offering includes 11.1 million shares or pre-funded warrants, accompanied by warrants to purchase up to 11.1 million shares at a price of $0.45 per share. The net proceeds from the offering will be used for research and development, working capital, and general corporate purposes. Altamira Therapeutics’ shares were trading down 16.43% pre-market.
- RNA delivery technology company Altamira Therapeutics (NASDAQ:CYTO) said on Thursday that it priced an ~$5M public offering of shares.
- The company is offering 11.1M shares, or pre-funded warrants in lieu thereof, accompanied by warrants to purchase up to 11.1M shares at $0.45 per share.
- The warrants will have an exercise price of $0.45 per share.
- The offering is expected to close on or about July 10.
- The net proceeds are intended to be used for research and development, working capital and general corporate purposes.
- CYTO shares were trading -16.43% pre-market.
Source: SeekingAlpha